[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ovarian-cysts\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ovarian-cysts":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,47,76,98,129,161,182],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100612051","timing-of-lng-iud-insertion-and-ovarian-cyst-formation-100612051",false,"NCT07248553","Timing of LNG-IUD Insertion and Ovarian Cyst Formation","The Effect of Levonorgestrel-Containing Intrauterine Device (LNG-IUD) Insertion Timing on Ovarian Cyst Development According to the Early and Late Follicular and Luteal Phases","LNG-IUD TIMING","Inclusion Criteria:\n\n* Reproductive age: 18-45 years\n* Patients with indications for LNG-IUD (levonorgestrel-containing intrauterine device) insertion (abnormal uterine bleeding, menorrhagia, dysmenorrhea, endometriosis, adenomyosis, hormonally induced dysfunctional uterine bleeding, endometrial protection in women receiving postmenopausal hormone replacement therapy, and endouterine hyperplasia without atypia)\n* Patients without contraindications for LNG-IUD (no suspected pregnancy, no serious uterine anomalies (Müllerian anomalies), no active pelvic infection, no history of serious liver disease or breast cancer, and no anatomical or clinical contraindications to IUD insertion) will be included.\n* They must not have used oral contraceptives for at least 3 months.\n* The previous IUD must have been removed at least 1 year prior.\n* Those who signed the informed consent form and agreed to participate voluntarily will be included in the study.\n* Those who have not used steroidal anti-inflammatory drugs within 24 hours of insertion of a levonorgestrel-containing IUD will be included in the study.\n\nExclusion Criteria:\n\n* Pregnancy history or current pregnancy\n* Patients using hormone therapy\n* Patients with adnexal masses\n* Patients with severe systemic diseases (uncontrolled diabetes, advanced cardiovascular disease, active malignancies (especially hormone-sensitive ones), advanced liver or kidney failure, systemic connective tissue diseases)\n* Patients with contraindications to the levonorgestrel IUD (suspected pregnancy, severe uterine anomaly, active pelvic infection, severe liver disease, or a history of breast cancer, anatomical or clinical obstacles to intrauterine device insertion)\n* Patients with psychological disabilities\n* Patients who refuse to sign the informed consent form\n* Patients who cannot be followed up will not be included in the study.","FEMALE","18 Years","45 Years",{"count":21,"type":22},60,"ESTIMATED","1 Year","OBSERVATIONAL","In this prospective observational study, the effect of timing of insertion (early\u002Flate follicular; early\u002Flate luteal) on ovarian cyst development in women receiving an LNG-IUD will be assessed ultrasonographically at months 0, 3, 6, and 12. Secondary outcomes include cyst size\u002Fstructure, bleeding pattern, pain, and other adverse events.",[27,28,29],"Ovarian Cysts","Menstrual Cycle","Intrauterine Device (IUD)",[31,32,33],"Levonorgestrel-Releasing Intrauterine Device","Menstrual Cycle Phase","Ovarian Cyst","RECRUITING","2025-11-18",{"date":37,"type":38},"2025-11-25","ACTUAL",{"date":40,"type":38},"2025-06-01",{"date":42,"type":22},"2026-06-01",{"name":44,"class":45},"Gaziosmanpasa Research and Education Hospital","OTHER_GOV",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100590221","a-randomized-controlled-trial-study-comparing-adnexal-surgery-by-vnotes-or-laparoscopy-100590221","NCT06964594","A Randomized Controlled Trial Study Comparing Adnexal Surgery by vNOTES or Laparoscopy","ADNOLA","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the trial.\n* Female aged 18 years or above.\n* Diagnosed with adnexal pathology or subject for prophylactic BSO.\n\nExclusion Criteria:\n\n* Female participant who is pregnant or planning pregnancy during course of the trial.\n* Scheduled elective surgery or other procedures requiring general anaesthesia during the trial.\n* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.\n* Patients taking opioids or other painkillers routinely pre-operatively.\n* Patients with chronic pelvic pain.\n* Patients with surgical contraindication; previous hysterectomy, history of rectal surgery, suspected or confirmed endometriosis, suspected malignancy, suspected obliteration of the pouch of Douglas following severe PID or other causes, active lower genital tract infection, pregnancy.\n* Failure to provide written informed consent prior to surgery",{"count":55,"type":22},200,"INTERVENTIONAL",[58],"NA","The aim with the study is to compare postoperative pain after vNOTES adnexal surgery versus laparoscopic adnexal surgery.\n\nWomen aged 18 and above with an indication for adnexal surgery for benign gynecological pathology or prophylactic reasons will be able to participate.\n\nAfter surgery the participants will answer a questioner, twice a day in seven days, about postoperative pain and how many units of analgesics they used.\n\nAdnexal surgery is one of the most common surgical procedures performed in women and can either be performed to treat pathology as ovarian cysts or prophylactically in case of hereditary genetic alterations.\n\nA laparoscopic technique is currently considered as gold standard for adnexal procedures. The latest advancement in minimally invasive surgery is vNOTES (vaginal natural orifice transluminal endoscopy), in which the entrance to the abdomen is performed by an anterior or more commonly posterior colpotomy rather than via the abdominal wall. The NOTABLE trial was a RCT showing that vNOTES adnexectomy was non-inferior to laparoscopy for successful removal of benign adnexa without conversion (Baekelandt). vNOTES adnexectomy had shorter surgical time, less use of analgesics and lower self-assessed VAS scores the first week post-operatively. The aim with our study is to compare postoperative pain after vNOTES versus laparoscopic adnexal surgery.",[27,61,62],"Laparoscopic Gynecologic Surgery","vNOTES",[64],"ADNOLA - A randomized controlled trial study comparing adnexal surgery by vNOTES or laparoscopy","NOT_YET_RECRUITING","2025-05-01",{"date":68,"type":38},"2025-05-09",{"date":70,"type":22},"2025-10-01",{"date":72,"type":22},"2028-12",{"name":74,"class":75},"Region Skane","OTHER",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":56,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":46},"100586281","comparison-between-electrosurgical-energy-and-hemostatic-sealants-on-hemostasis-in-laparoscopic-ovarian-cystectomy-100586281","NCT06913335","Comparison Between Electrosurgical Energy and Hemostatic Sealants on Hemostasis in Laparoscopic Ovarian Cystectomy","Optimizing Hemostasis in Laparoscopic Ovarian Cystectomy: A Comparison Between Electrosurgical Energy and Hemostatic Sealants.","Inclusion Criteria:\n\n* Age ≥ 18 years old.\n* Women with unilateral or bilateral benign ovarian cyst provisionally diagnosed by ultrasound and normal tumor markers.\n* Women fit for laparoscopic surgery\n\nExclusion Criteria:\n\n* Pregnant women.\n* Postmenopausal women.\n* Premenarchal girls.\n* Women with a history of recent pelvic or abdominal radiotherapy.\n* Women with serious concurrent systemic disorders.\n* Known ovarian malignancy provisionally diagnosed by ultrasound (US) or tumor markers.\n* Women with coagulopathy or bleeding disorders.","50 Years",{"count":85,"type":22},58,[58],"The aim of this study is to compare between the effect of using electrosurgical energy and hemostatic sealant for hemostasis in laparoscopic cystectomy for ovarian cysts.",[27],"2025-04-05",{"date":91,"type":38},"2025-04-09",{"date":93,"type":38},"2025-04-01",{"date":95,"type":22},"2026-05-01",{"name":97,"class":75},"Kafrelsheikh University",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":56,"phases":107,"briefSummary":108,"conditions":109,"keywords":116,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":46},"100579755","a-clinical-study-on-the-feasibility-and-safety-of-abdominal-endoscopic-single-port-surgery-system-to-assist-gynecological-day-surgery-100579755","NCT06828419","A Clinical Study on the Feasibility and Safety of Abdominal Endoscopic Single-port Surgery System to Assist Gynecological Day Surgery","Inclusion Criteria:\n\n1. Women aged 18 to 75 years old, with a body mass index (BMI) of no more than 32 kg\u002Fm2;\n2. Conscious, no history of mental illness, accompanied by an adult during the perioperative period;\n3. Educate the subjects, who are willing to undergo day surgery, understand and accept the surgical method and anesthesia method;\n4. Subjects and families understand perioperative care and are willing and able to complete post-discharge care;\n5. Elective surgery, no serious complications affecting the operation and prognosis, aCCI age adjusted comorbidity index 0 points;\n6. According to the adhesion risk scoring system of European Anti-Adhesions in Gynaecology Expert Panel (ANGEL), the adhesion risk was divided into three levels: high, medium and low. Subjects with low risk (0 to 12 points) and abdominal wall scarring and pelvic cavity B-ultrasonography do not indicate obvious pelvic cavity adhesion wiil be included.\n\nExclusion Criteria:\n\n1. Moderate and high-risk patients will be excluded based on ANGEL adhesion risk scoring system;\n2. Subjects with hemorrhagic rupture of ectopic pregnancy and unstable vital signs;\n3. Genital tract infection or in the acute phase of systemic infection;\n4. Subjects on long-term anticoagulant therapy or with coagulation dysfunction;\n5. Subjects have severe heart and lung disease, liver and kidney dysfunction, and cannot tolerate anesthesia;\n6. A history of abdominal or diaphragmatic hernia, abnormal umbilical cord development, or umbilical surgery;\n7. Not willing to undergo endoscopic surgery;\n8. Participated in other drug and device clinical trials within 3 months before surgery.","75 Years",{"count":106,"type":22},63,[58],"In this study, a prospective study is used to select patients who will undergo intra-abdominal endoscopic single-port surgery system for benign gynecological diseases from February 2025 to December 2026 in the Second Affiliated Hospital of Wenzhou Medical University, including hysterectomy, myomectomy, ovarian cyst removal and adnexectomy. The study will perform statistical analysis to evaluate the feasibility and the main factors affecting the safety of intra-abdominal endoscopic single-port surgery system(SR-ENS-600) used in gynecological day surgery.",[110,111,27,112,113,114,115],"Adenopathy","Uterine Fibroids","Adnexal Mass","Ovarian Diseases","Adnexal Cyst","Adnexal Diseases",[117,118,119],"robotic-assisted laparoscopic single-site surgery (R-LESS)","single-port robot system (SPRS)","day surgery","2025-03-27",{"date":122,"type":38},"2025-04-03",{"date":124,"type":22},"2025-04-10",{"date":126,"type":22},"2026-12-31",{"name":128,"class":75},"Second Affiliated Hospital of Wenzhou Medical University",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":56,"phases":140,"briefSummary":141,"conditions":142,"keywords":148,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":46},"100565162","mirrors-frozen---comparing-open-vs-robotic-surgery-in-the-management-of-women-with-complex-pelvic-adnexal-masses--8cm-100565162","NCT06638593","MIRRORS-FROZEN - Comparing Open Vs Robotic Surgery in the Management of Women with Complex Pelvic Adnexal Masses ≤ 8cm.","MIRRORS-FROZEN - a Pilot Randomised Controlled Trial (RCT) Comparing Open Vs Robotic Surgery in the Management of Women with Complex Pelvic Adnexal Masses ≤ 8cm.","MIRRORS-FROZEN","Inclusion Criteria:\n\n* Complex adnexal Pelvic mass\u002Fes ≤8 cm with no malignant disease outside the adnexae on CT or MRI.\n* Women aged ≥18 \\& ≤100 years old.\n* Patients who had given their signed and written informed consent\n\nExclusion Criteria:\n\n* Adnexal pelvic mass \\> 8 cm.\n* Radiological or histological or cytological evidence of stage III or IV disease.\n* Lack of capacity to understand and give informed consent.\n* Patients not suitable for laparoscopic surgery, such as but not limited to those with severe aortic stenosis.\n* Any patient randomized to either of the study arms and found to have disease which appears greater than stage 1 will be withdrawn from the trial and treated according to the national guidelines","100 Years",{"count":139,"type":22},40,[58],"Adnexal masses are growths that can form in the ovaries or fallopian tubes for different reasons, such as hormonal changes, infection, or cancer. These masses may cause pelvic discomfort, pain, constipation, or no symptoms at all. When adnexal masses are found on scans, they are described in a certain way to indicate if they could represent early-stage cancer, and the word \"complex\" is used to refer to these masses. Surgery is often recommended, where the mass is removed and examined under the microscope during surgery in a process called (frozen section analysis); to determine its true nature.\n\nIt is still difficult to confirm cancer before surgery, and many of these masses turn out to be benign (not cancerous) or borderline (slow-growing tumours). Currently, doctors use open surgery with a cut from at least the belly button to the pubic bone to remove these masses. Patients with a cancer diagnosis will then have more surgical steps including assessment and sampling of various areas inside the abdomen (known as staging surgery) to see how far the cancer has spread.\n\nRecovery after open surgery can be long and painful, with a slow return to normal daily activities. The trial investigators know from practice that robotic surgery has replaced open surgery for most benign adnexal diseases and other types of women's cancers, such as womb cancer. Recovery is quicker, with less pain and blood loss, allowing for a faster return to daily activities.\n\nThis study, MIRRORS-FROZEN (pilot), compares robotic versus the standard open surgery in managing women with complex adnexal masses of eight centimetres or less. The hope is to decrease the need for open surgery in patients with benign or borderline disease and to assess if robotic surgery has similar, worse, or better outcomes for patients with cancer.\n\nMIRRORS-FROZEN is funded by Intuitive Foundation and GRACE Charity. The investigators will establish the feasibility of conducting a large multicentre randomized controlled trial in the future comparing certain cancer outcomes between robotic and open surgery.",[143,144,27,145,146,114,147],"Ovarian Cancer","Ovarian Mass","Fallopian Tube Neoplasms","Adnexal Carcinoma","Adnexal Masses",[149,150,151],"Robotic","adnexal masses","Adnexal cysts","2024-10-10",{"date":154,"type":38},"2024-10-15",{"date":156,"type":38},"2024-09-23",{"date":158,"type":22},"2027-02-01",{"name":160,"class":75},"Royal Surrey County Hospital NHS Foundation Trust",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":180,"locationsCount":46},"100504004","improved-diagnosis-of-ovarian-cancer-100504004","NCT05842629","Improved Diagnosis of Ovarian Cancer","Patients with an adnexal mass observed at ultrasonography.",{"count":168,"type":22},1700,"After implementation of systematic image description of adnexal masses, we aim to improve and evaluate our use of available imaging methods and biomarkers for classifying adnexal masses and distinguishing between benign and malignant adnexal masses in the hands of clinicians in Central Denmark Region.\n\nSecondarily, we want to improve our management of adnexal masses by evaluating the complications and longitudinal changes in conservatively managed adnexal masses.\n\nData is registered prospectively but analyzed retrospectively.",[171,143,27,112,172,146,173],"Ovarian Neoplasms","Adnexal Lesion","Adnexal Neoplasm","2024-05-08",{"date":176,"type":38},"2024-05-09",{"date":178,"type":38},"2021-05-15",{"date":72,"type":22},{"name":181,"class":75},"University of Aarhus",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":193,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":46},"100497919","improved-diagnosis-of-ovarian-cancer-by-use-of-circulating-tumor-dna-as-a-biomarker-100497919","NCT05763511","Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker","Inclusion Criteria:\n\n* Suspected ovarian neoplasm\n* Informed consent\n\nExclusion Criteria:\n\n* Inability to give informed consent\n* Previous ovarian cancer diagnosis",{"count":189,"type":22},300,"This project investigates circulating tumor DNA (ctDNA) in patients with suspected ovarian malignancy.\n\nWe hypothesize that measurement of ctDNA in women with suspected ovarian cancer can improve the diagnostic efficiency for preoperative differentiation between benign and malignant masses.\n\nSpecifically, we hope to determine the diagnostic efficiency of ctDNA alone and ctDNA in combination with imaging modalities (ultrasonography, MRI, PET-CT) and CA 125 for preoperative differentiation between benign and malignant adnexal masses. Based on this, we hope to develop an improved diagnostic algorithm.\n\nThe mutational profile and relation to tumour type, stage, treatment response and prognosis will be explored.\n\nAnalyses of blood and tissue samples will be used to examine the disease development and biology.\n\nBlood samples, tumour tissue and data on imaging modalities as well as CA 125 will be collected prospectively in consecutive women referred to Aarhus University Hospital.",[171,192,27],"Ovary Cancer",{"date":176,"type":38},{"date":195,"type":38},"2022-07-01",{"date":197,"type":22},"2029-05-04",{"name":181,"class":75}]